Evidence map›Paper›PMID 39290545›Full record

ArticleJournal of advanced pharmaceutical technology & research

Glucomannan is a promising isoniazid's enhancer that inducing macrophage phagocytosis.

Bernadette Dian Novita, Widya Wasiyastuti, Yudy Tjahjono, Hendy Wijaya, Wuryanto Hadinugroho, Sumi Wijaya, Lisa Soegianto, Imelda Theodora, Elisabeth Tri Wahyuni Widoretno, Kevin Samsudin and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of advanced pharmaceutical technology & research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Bernadette Dian NovitaDepartment of Pharmacology and Therapy, Faculty of Medicine, Widya Mandala Surabaya Catholic University, Surabaya, Indonesia.
Widya WasiyastutiDepartment of Physiology, Faculty of Medicine, Gadjah Mada University, Yogyakarta, Indonesia.
Yudy TjahjonoDepartment of Biomedicine, Faculty of Pharmacy, Widya Mandala Surabaya Catholic University, Surabaya, Indonesia.
Hendy WijayaDepartment of Biomedicine, Faculty of Pharmacy, Widya Mandala Surabaya Catholic University, Surabaya, Indonesia.
Wuryanto HadinugrohoDepartment of Biomedicine, Faculty of Pharmacy, Widya Mandala Surabaya Catholic University, Surabaya, Indonesia.
Sumi WijayaDepartment of Biomedicine, Faculty of Pharmacy, Widya Mandala Surabaya Catholic University, Surabaya, Indonesia.
Lisa SoegiantoDepartment of Biomedicine, Faculty of Pharmacy, Widya Mandala Surabaya Catholic University, Surabaya, Indonesia.
Imelda TheodoraDepartment of Pathology, Faculty of Medicine, Widya Mandala Surabaya Catholic University, Surabaya, Indonesia.
Elisabeth Tri Wahyuni WidoretnoDepartment of Internal Medicine, Faculty of Medicine, Widya Mandala Surabaya Catholic University, Surabaya, Indonesia.
Kevin SamsudinDepartment of Internal Medicine, Faculty of Medicine, Widya Mandala Surabaya Catholic University, Surabaya, Indonesia.
Alvin JulianDepartment of Internal Medicine, Faculty of Medicine, Widya Mandala Surabaya Catholic University, Surabaya, Indonesia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Isoniazid (INH) is a frontline antituberculosis agent effective against

Indexed as

Characteristic profileglucomannanisoniazidmacrophage phagocytosisMycobacterium tuberculosis

Identifiers

PMID39290545
PMCPMC11404426

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.